

IR REPORT

OncoLaB

Investment Objective

Timeline	Q1 2025
Desired Investment Amount	USD 1M
Desired Company Valuation	USD 10M (Pre-money Value)
Investment Stage	Pre A

Capital Allocation Plan

R&D and Personnel Costs
Sales and Marketing
Clinical Preparation (GLP, GMP, IND)

Company Information

Establishment	2024. 05
Address	SB Plaza, Osong Life 1-ro, Cheongju, Chungcheongbuk-do
Member	7

Personnel Introduction

Jongseong Kim CEO	Ph.D. from Georgia Tech Former Research Fellow at Harvard Medical School
Andrew Lyon CSO	Former Dean, Department of Chemistry, Georgia Tech Former Dean, College of Engineering, Chapman University Co-founder, Selsym
Doogie Oh CTO	Ph.D. in Science, Georgia Tech Former Researcher, Harvard University

Investment History (KRW 1M)

Timeline	Investors	Amount
2024. 06.	Chungbuk Creative Economy	300
2024. 11	BTB Ventures	200
Total		500

Shareholding Structures

Jongseong Kim	74.2%
Doogie Oh	4.6%
Others	16.6%
Chungbuk Creative Economy & Chungcheong Region Angel Bridge Fund	4.6%

Financial Status (KRD 1M)

Capital	54.2
Borrowings	-
2023 Revenue	-
2024 Projected Revenue	-

Source : Company Information

OncoLab

Development of the next-generation cancer treatment platform
Antibody-conjugated NanoGel, ANGel

Investment Highlights

- Providing Therapeutic Solution for Refractory Triple-Negative Breast Cancer with ANGel-equipped Immune Checkpoint Inhibitors
- Innovative subcutaneous injection technology designed to secure exclusive positioning in the \$1 trillion (2030) immune-oncology market, addressing challenges posed by the impending expiration of existing drug patents
- Enabling convenience of formulation and expansion of indications using existing therapeutics while offering lower development costs and higher success rates compared to new drugs or ADCs


+ Target Market Analysis

- The solid tumor treatment market, valued at approximately KRW 240 trillion in 2022, is anticipated to grow nearly threefold to KRW 690 trillion by 2032. However, third-generation immune checkpoint inhibitors and cell therapies are constrained by low response rates
- The market for cancer treatment platforms is expected to achieve double-digit annual growth, addressing unmet needs for innovative solutions that combine superior drug delivery, efficacy, and sustainability
- Global pharmaceutical companies facing patent expirations are actively developing market defense strategies through innovative platforms

+ Service and Product Overview

Innovative ANGel Platform for Cancer Treatment

- **Efficient Delivery:** ANGel enables high drug delivery through subcutaneous injection and enhances efficacy with multi-specific antibody therapies.
- **Superior Sustainability:** It achieves long-lasting effects through adhesion to subcutaneous tissue.
- **Personalized Therapies:** Designed for bio-friendly production, ANGel supports personalized therapy development.
- **Scalable Production:** Core technologies ensure scalability for Phase III clinical trials.
- **Promising Efficacy:** ANGel shows superior efficacy and lower toxicity for TNBC compared to competitor drugs.



[ANGel subcutaneous injection method and tumor size and survival rate results from preclinical trials in triple-negative breast cancer animal models]

+ Differentiation

1. Survival rate is a key metric for TNBC treatment. ANGel demonstrates a **100% improvement in overall survival (OS)**, outperforming existing treatments such as **Keytruda**, which shows a 30% OS increase, and **Trodelyv**, which achieves a 50% OS increase.
2. Compared to conventional chemotherapy, ANGel technology demonstrates toxicity levels **comparable to Keytruda** and **50% lower than Trodelvy**, emphasizing its **superior safety profile**

+ Development Progress and Business Strategy

	Process	Candidate	Preclinical	IND	Phase 1	Phase 2	Phase 3	NDA
Product Name	ANGel-TNBC01 (TNBC treatment)			Q4 26' (Expected)	Q1 27' (Expected)	L/O		
	ANGel-TNBC02 (TNBC treatment)			Q4 27' (Expected)	Q1 28' (Expected)	L/O		
	ANGel-PSC01 (Prostate cancer treatment)		4Q 26'					
	ANGel-PSC02 (Prostate cancer treatment)		2Q 27'					

Business Model

Our business model centers on **technology transfer to global pharmaceutical companies**, enabling extensive supply of treatments through their established sales networks.

- **Unmet Need in TNBC:** Triple-negative breast cancer (TNBC) lacks effective treatment options, leading to **low competition** but **high demand** in this field.
- **Improved OS:** ANGel technology significantly extends overall survival (OS), addressing the strong demand for effective therapies in hospitals.
- **Global Reach:** Leveraging global pharmaceutical companies' networks, ANGel technology is expected to achieve extensive sales, with **Alteogen's technology transfer for Merck's Keytruda** serving as a successful reference model.

Marketing Strategy

- **Partnerships:** Collaborate with global pharma companies via bio conventions for research and technology transfer.
- **Acceleration Programs:** Expand through support in Boston, Silicon Valley, and Basel.
- **K-Bio Bridge:** Network with pharma and investors for global outreach.
- **Boston Connections:** Leverage ties with Prof. Timothy Springer for ANGel promotion.
- **Nanogel Expertise:** Partner with Prof. Andrew Lyon and ventures for global scaling.

+ Company Overview

Company Overview and Vision

Members: CEO Jongseong Kim, founder of OncoLab, developed bioreactive nanogels at Georgia Tech and conducted immunotherapy research at Harvard Medical School. With over 20 years of experience in nanogel development and diagnostics, he envisions a new cancer treatment business model targeting the global pharmaceutical market. Professor Andrew Lyon, a nanogel technology pioneer, has led groundbreaking research and founded multiple biotech ventures based on nanogel technologies. Dr. Doogie Oh, an expert in biophysics and quantitative analysis, aims to integrate AI technologies into future cancer therapy development.

Vision : **innovative, patient-centric therapies** that improve survival rates and set new standards in cancer care globally.

Patents, Publications, and Awards

+ Patent (IP)

Registration	10-2613420	Deformable hydrogel particles and pharmaceutical composition for treatment of cancer comprising the same	KOR
Application	US 17-911626	Deformable hydrogel particles and pharmaceutical composition for cancer treatment comprising same	US
Application	EP 2021-772135	Deformable hydrogel particles and pharmaceutical composition for cancer treatment comprising same	EU
Application	CN 2021-80021424	Deformable hydrogel particles and pharmaceutical composition for cancer treatment comprising same	CHN

+ Publication

Advanced Healthcare Materials Antibody-Conjugated Nanogel with Two Immune Checkpoint Inhibitors for Enhanced Cancer Immunotherapy **IF 10**

- Selected for the Deep Tech TIPS startup commercialization project by the Chungbuk Creative Economy Innovation Center, with KRW 15 billion in government funding over three years (2024.09)